This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jun 30;391(10140):2577-2578.

doi: 10.1016/S0140-6736(18)30936-X. Epub 2018 Jun 23.

Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?

Christopher K Rayner¹, Michael Horowitz²

Affiliations

Affiliations

¹ Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide 5000, SA, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA, Australia.
² Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide 5000, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, Australia. Electronic address: michael.horowitz@adelaide.edu.au.

PMID: 29945728
DOI: 10.1016/S0140-6736(18)30936-X

Comment

Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?

Christopher K Rayner et al. Lancet. 2018.

. 2018 Jun 30;391(10140):2577-2578.

doi: 10.1016/S0140-6736(18)30936-X. Epub 2018 Jun 23.

Authors

Christopher K Rayner¹, Michael Horowitz²

Affiliations

¹ Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide 5000, SA, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA, Australia.
² Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide 5000, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, Australia. Electronic address: michael.horowitz@adelaide.edu.au.

PMID: 29945728
DOI: 10.1016/S0140-6736(18)30936-X

No abstract available

PubMed Disclaimer

Comment on

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Ambery P, et al. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. Lancet. 2018. PMID: 29945727 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations